Overview

This trial is active, not recruiting.

Conditions bleb vascularity, conjunctival scarring
Treatment bevacizumab
Phase phase 4
Target VEGF
Sponsor Capital Medical University
Start date December 2008
End date March 2009
Trial size 30 participants
Trial identifier NCT00815594, 2008TR-LX-001

Summary

The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment

Primary Outcomes

Measure
bleb vascular change
time frame: one day, one week, one month

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

Inclusion Criteria: - Glaucoma patients after trabeculectomy whose bleb is hyperaemia Exclusion Criteria: - Affected eye has normal IOP - Not allergic with Avastin

Additional Information

Official title Bleb Vascularity Change After Subconjunctival Injection of Bevacizumab
Principal investigator Liu Xuan, M.D.
Trial information was received from ClinicalTrials.gov and was last updated in December 2008.
Information provided to ClinicalTrials.gov by Capital Medical University.